These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17404699)

  • 1. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.
    Teipel SJ; Ewers M; Reisig V; Schweikert B; Hampel H; Happich M
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):330-6. PubMed ID: 17404699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan.
    Ikeda S; Yamada Y; Ikegami N
    Dement Geriatr Cogn Disord; 2002; 13(1):33-9. PubMed ID: 11731713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
    Fuh JL; Wang SJ
    Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
    Getsios D; Blume S; Ishak KJ; Maclaine GD
    Pharmacoeconomics; 2010; 28(5):411-27. PubMed ID: 20402542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.
    Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
    Clin Ther; 1999 Jul; 21(7):1230-40. PubMed ID: 10463520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donepezil. Pharmacoeconomic implications of therapy.
    Foster RH; Plosker GL
    Pharmacoeconomics; 1999 Jul; 16(1):99-114. PubMed ID: 10539126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
    O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S
    J Am Geriatr Soc; 1999 May; 47(5):570-8. PubMed ID: 10323651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
    Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
    Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
    Neumann PJ; Hermann RC; Kuntz KM; Araki SS; Duff SB; Leon J; Berenbaum PA; Goldman PA; Williams LW; Weinstein MC
    Neurology; 1999 Apr; 52(6):1138-45. PubMed ID: 10214734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications.
    Fagnani F; Lafuma A; Pechevis M; Rigaud AS; Traykov L; Seux ML; Forette F
    Dement Geriatr Cogn Disord; 2004; 17(1-2):5-13. PubMed ID: 14560059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil.
    Stewart A; Phillips R; Dempsey G
    Int J Geriatr Psychiatry; 1998 Jul; 13(7):445-53. PubMed ID: 9695032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.
    Getsios D; Blume S; Ishak KJ; Maclaine G; Hernández L
    Alzheimers Dement; 2012 Jan; 8(1):22-30. PubMed ID: 21420366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
    López-Bastida J; Hart W; García-Pérez L; Linertová R
    J Alzheimers Dis; 2009; 16(2):399-407. PubMed ID: 19221429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donepezil use in managed Medicare: effect on health care costs and utilization.
    Fillit H; Gutterman EM; Lewis B
    Clin Ther; 1999 Dec; 21(12):2173-85. PubMed ID: 10645761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.
    Hartz S; Getsios D; Tao S; Blume S; Maclaine G
    BMC Neurol; 2012 Feb; 12():2. PubMed ID: 22316501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of donepezil in moderate to severe Alzheimer disease.
    Feldman H; Gauthier S; Hecker J; Vellas B; Hux M; Xu Y; Schwam EM; Shah S; Mastey V;
    Neurology; 2004 Aug; 63(4):644-50. PubMed ID: 15326236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AD2000: donepezil in Alzheimer's disease.
    Schneider LS
    Lancet; 2004 Jun; 363(9427):2100-1. PubMed ID: 15220027
    [No Abstract]   [Full Text] [Related]  

  • 19. An economic evaluation of donepezil in the treatment of Alzheimer's disease.
    Small GW; Donohue JA; Brooks RL
    Clin Ther; 1998; 20(4):838-50. PubMed ID: 9737841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of a cost-utility model of donepezil for Alzheimer's disease.
    Peters JL; Anderson R; Hoyle M; Hyde C
    Int J Technol Assess Health Care; 2013 Apr; 29(2):147-54. PubMed ID: 23514698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.